While in normal rats, PPAR agonists cause peroxisome proliferation, thereby enhancing the potential for liver tumor formation, on the other hand, in NAFLD-NASH models, the tumor is induced by a combination of factors that appears to be blocked by saroglitazar in this study. Here, PPARA is linked to metabolic dysfunction-associated steatohepatitis.